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Young-Hak Kim, MD,* Jae-Joong Kim, MD, PHD,* Seong-Wook Park, MD, PHD,*
Gary S. Mintz, MD,† Seung-Jung Park, MD, PHD*
Seoul, Korea; and New York, New York
Objectives This study compared intravascular ultrasound (IVUS) findings at drug-eluting stent (DES) and bare-metal stent
(BMS) sites in patients with very late stent thrombosis (VLST).
Background VLST is being increasingly identified since the introduction of DES. VLST can also develop after BMS placement,
but the underlying mechanisms remain unknown.
Methods A total of 30 consecutive VLST patients with acute myocardial infarction (DES, n  23; BMS, n  7) were en-
rolled. Patients underwent IVUS examination before coronary angioplasty.
Results The baseline characteristics were similar for the 2 groups, with the exception of reference vessel size, lesion
length, stent length, minimal lumen diameter, and diameter stenosis after the procedure. Overall, VLST occurred
at a mean 50.8  36.2 months after the index procedure, and occurred earlier after DES than BMS (33.2 
12.5 months vs. 108.4  26.5 months, p  0.001). IVUS variables were generally similar for the 2 groups. How-
ever, plaque burden at the distal reference segment, stent, and neointimal area of the in-stent segment were
smaller in the DES group. Stent malapposition was observed in 73.9% of DES patients, but in no BMS patients
(p  0.001). Disease progression with neointimal rupture within the stent was observed in 10 DES patients
(43.5%) and 7 BMS patients (100%; p  0.010).
Conclusions Stent malapposition was unique to DES-related VLST, whereas disease progression with neointimal rupture was
more common in BMS patients. These findings suggest that different biological mechanisms underlie VLST de-
velopment depending upon the stent type. (J Am Coll Cardiol 2010;55:1936–42) © 2010 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.10.077N
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srug-eluting stents (DES) reduce the risk of restenosis
ompared with bare-metal stents (BMS) (1,2). However,
oncerns have been raised regarding the long-term safety of
ES, especially in terms of very late stent thrombosis
VLST), namely, thrombosis occurring beyond 1 year after
eployment (3–5). VLST as a rare, but potentially life-
hreatening complication has been increasingly recognized
ince the introduction of DES. Several studies have shown
hat delayed arterial healing and stent malapposition may be
mportant causes of VLST after DES placement (6–9).
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eoul, Korea; and the †Cardiovascular Research Foundation, New York, New York.
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epublic of Korea (A090264). Dr. Mintz has received grant support from Boston
cientific and Volcano Corp., and has a consulting relationship with Volcano Corp.s
Manuscript received July 20, 2009; revised manuscript received September 10,
009, accepted October 8, 2009.evertheless, although VLST is typically associated with
ES, it has also been reported after BMS placement (10);
nd little is known about the mechanisms underlying
MS-related VLST. The present study compared intravas-
ular ultrasound (IVUS) findings in DES-treated patients
ersus BMS-treated patients who presented with VLST.
See page 1943
ethods
tudy population. The Asan Medical Center clinical and
VUS laboratory database included 38 patients who pre-
ented with VLST between October 2004 and April 2009.
f those, 30 VLST patients underwent IVUS before
oronary intervention and comprised the study population.
here were 23 patients with VLST after DES (19 Cypher
tents, Cordis–Johnson & Johnson, Bridgewater, New Jer-
ey; and 4 Taxus stents, Boston Scientific, Natick, Massa-
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May 4, 2010:1936–42 IVUS in Very Late Stent Thrombosishusetts) placement and 7 patients with VLST after BMS
lacement. No patients received thrombolytic therapy
r thrombus aspiration before IVUS examination. VLST was
efined as acute myocardial infarction and angiographic con-
rmation of thrombotic stent occlusion occurring beyond 1
ear after stent implantation in accordance with the Academic
esearch Consortium definition of VLST (11). Acute myo-
ardial infarction was diagnosed as typical rise and fall of
ardiac injury markers with sudden onset of resting chest pain
asting20 min and new ischemic electrocardiogram changes.
uantitative coronary angiographic analysis. Coronary
ngiograms were independently analyzed by experienced an-
iographers unaware of the study goal. Percent diameter
tenosis, minimal lumen diameter, and reference diameter
sing an on-line quantitative angiographic analysis system
CASS 2.0, Pie Medical Imaging, Eindhoven, the Nether-
ands) were measured before pre-dilation and after the stenting
rocedure. Angiographic measurements were made during
iastole after intracoronary nitroglycerin administration using a
uiding catheter to calibrate magnification.
mage acquisition and analysis. The IVUS imaging was
erformed after intracoronary administration of 0.2 mg nitro-
lycerin using a motorized transducer pullback system (0.5
m/s) and a commercial scanner (SCIMED/Boston Scien-
ific, Natick, Massachusetts) that consisted of a rotating 40 mHz
ransducer within a 3.2- or 2.6-F imaging sheath. The IVUS
mages were recorded on s-VHS videotape or computer disk and
nalyzed by personnel unaware of the type of stent implanted.
Using computerized planimetry, the external elastic mem-
rane, lumen, and stent cross-sectional area (CSA [mm2])
ere measured every 1 mm in the stented and reference
egments; and volumes were calculated using Simpson’s rule
Clinical CharacteristicsTable 1 Clinical Characteristics
Variables DES
Age, yrs 53.
Sex, male/female
Risk factors
Current smoker 14
Diabetes mellitus 6
Hypertension 13
Hypercholesterolemia, 200 mg/dl 6
Diagnosis at the index procedure
Stable angina 13
Acute coronary syndrome 10
Left ventricular ejection fraction, % 57.
Months after the index procedure 33.
Clinical presentation at time of VLST
STEMI 18
NSTEMI 5
Antiplatelet therapy at time of VLST
Aspirin plus clopidogrel 2
Aspirin 16
None 5
Values are mean  SD, n, or n (%).
BMS  bare-metal stent(s); DES  drug-eluting stent(s); NSTEMI  non
elevation myocardial infarction; VLST  very late stent thrombosis.nd normalized for analysis length
o yield mean values of external
lastic membrane, stent, and lu-
en CSA. The proximal and dis-
al reference segments selected for
nalysis were the most normal-
ooking cross-sections within 5
m proximal or distal to the lesion
ut before any side branch. Stent
alapposition was defined as sep-
ration of at least 1 stent strut from
he intimal surface of the arterial wall that was not overlapping
side branch with evidence of blood flow (speckling) behind
he strut. Neointimal area was calculated as the stent minus
umen CSA, and the neointima volume index as the neointima
olume divided by stent volume.
tatistical analysis. Data are expressed as mean  SD for
ontinuous variables and frequencies for categorical vari-
bles. Continuous variables were compared using Mann-
hitney U tests, and categorical variables using the chi-
quare test or Fisher exact test. Statistical significance was
efined as a 2-sided p value 0.05.
esults
linical characteristics. Baseline characteristics were gen-
rally similar for the 2 groups (Table 1). Overall, VLST
ccurred at a mean of 50.8  36.2 months after the index
rocedure, and occurred earlier in the DES group (33.2 
2.5 months, range 14.0 to 60.4 months) than in the BMS
roup (108.4  26.5 months, range 81.4 to 163.1 months;
 0.001). Clinical presentations at the time of VLST was
23) BMS (n  7) p Value
.9 61.7 6.3 0.077
7/0 0.290
) 5 (71.4) 1.000
) 2 (28.6) 1.000
) 4 (57.1) 1.000
) 3 (42.9) 0.661
0.390
) 2 (28.6)
) 5 (71.4)
.4 58.2  9.4 0.914
.5 108.4 26.5 0.001
1.000
) 6 (85.7)
) 1 (14.3)
0.625
0 (0)
) 4 (57.1)
) 3 (42.9)
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CSA  cross-sectional area
DES  drug-eluting stent(s)
IVUS  intravascular
ultrasound
VLST  very late stent
thrombosis(n 
2 11
17/6
(60.9
(26.1
(56.5
(26.1
(56.5
(43.5
9  10
2 12
(78.3
(21.7
(8.7)
(69.6
(21.7–ST-segment elevation myocardial infarction; STEMI  ST-segment
a
o
f
A
t
e
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IVUS in Very Late Stent Thrombosis May 4, 2010:1936–42cute ST-segment elevation myocardial infarction in 80.0%
f patients and non–ST-segment elevation myocardial in-
arction in 20.0% of patients.
Angiographic CharacteristicsTable 2 Angiographic Characteristics
Variables DES (
Target artery
Left main 0
Left anterior descending coronary 16
Left circumflex coronary 2
Right coronary 5
DES types
Cypher stent 19
Taxus stent 4
Stent size, mm 3.1
Number of stents per lesion 1.4
QCA at the index procedure
Lesion length, mm 25.5
Total stented length, mm 36.3
Reference vessel diameter, mm 2.97
Pre-intervention
Minimal lumen diameter, mm 0.81
Diameter stenosis, % 72.5
Post-intervention
Minimal lumen diameter, mm 2.70
Diameter stenosis, % 9.2
Values are n (%) or mean  SD.
QCA  quantitative coronary angiography; other abbreviations as in
Intravascular Ultrasound MeasurementsTable 3 Intravascular Ultrasound Measurem
Variables DES
Proximal reference segment, mm2
Mean EEM CSA 18.3
Mean lumen CSA 7.8
Mean plaque and media CSA 10.5
Distal reference segment, mm2
Mean EEM CSA 9.3
Mean lumen CSA 3.5
Mean plaque and media CSA 5.7
Stent segment
Total stented length, mm 32
Mean EEM CSA, mm2 19.5
Mean stent CSA, mm2 7.2
Mean lumen CSA, mm2 4.2
Minimal stent CSA, mm2 6.1
Mean neointimal area, mm2 3.0
Neointima volume index 0.4
ISA 17
Length, mm 7.4
CSA, mm2 4.5
Volume, mm3 17.8
Arc of ISA,° 158
Location
Proximal stent segment 6
Stent body 7
Distal stent segment 4Values are mean  SD or n (%).
CSA  cross-sectional area; EEM  external elastic membrane; ISA  incongiographic characteristics. The 2 groups differed in
erms of angiographic characteristics with respect to refer-
nce vessel size, lesion length, stent length, minimal lumen
3) BMS (n  7) p Value
0.248
1 (14.3)
2 (28.6)
0 (0)
4 (57.1)
3.6 0.5 0.062
1.3 0.5 0.980
15.4 4.0 0.006
23.7 9.9 0.001
3.66 0.70 0.010
1.09 0.84 0.384
73.2 18.1 0.896
4.08 1.01 0.001
5.9 9.9 0.003
1.
3) BMS (n  7) p Value
.30 18.60 5.87 0.856
.71 9.17 4.68 0.689
.01 9.42 3.52 0.799
.15 13.96 5.66 0.078
.78 4.22 1.84 0.438
.61 9.75 4.26 0.028
3.0 18.6 4.2 0.001
.07 18.31 4.17 0.774
.79 9.75 2.89 0.037
.40 4.73 1.64 0.564
.58 7.42 3.77 0.413
.15 5.03 1.78 0.014
.12 0.51 0.09 0.069
) 0 (0) 0.001
.49
.94
.99
0.8
)
)
)n  2
(0)
(69.6)
(8.7)
(21.7)
(82.6)
(17.4)
 0.3
 0.8
 10.8
 17.3
 0.40
 0.53
 16.9
 0.43
 8.5ents
(n  2
0 6
1 3
0 5
1 4
1 1
9 3
.9 1
5 6
5 1
0 1
5 1
7 1
2 0
(73.9
0 5
8 1
3 4
.1 5
(35.3
(41.2
(23.5mplete stent apposition; other abbreviations as in Table 1.
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May 4, 2010:1936–42 IVUS in Very Late Stent Thrombosisiameter, and diameter stenosis after the procedure (Table 2).
t the time of VLST, thrombotic stent occlusion was
omplete in 87.0% of patients and partial in 16.7% of
atients. No reflow developed in 10.0% of patients after the
rocedure. Two patients (6.7%) died of left ventricular
ailure after the procedure, and the remaining 28 patients
ere discharged alive.
VUS findings. Quantitative IVUS data are summarized in
able 3, and a representative case example is shown in
Figure 1 IVUS Images in a Patient With VLST
(A) A Cordis stent (4.0 mm  15 mm) was implanted at the ostial left anterior de
he presented with very late stent thrombosis (VLST). Coronary angiogram showed
(IVUS) images from the patient demonstrating very eccentric intra-stent plaque, fib
sequence of 6 image slices representing a 7.5-mm segment of the thrombosed st
stent struts are annotated); b  highly eccentric intrastent plaque; c  echolucen
rim of tissue just within the stent struts; d  site of plaque rupture at the shoulde
(note: the evacuated plaque cavity may extend distally as part of the intrastent pla
from a ruptured plaque in a nonstented arterial segment.igures 1A and 1B. Plaque rupture was observed in 2 DES
atients in the proximal reference segment and in 6 patients
DES, n  4; BMS, n  2) at the distal reference segment.
lthough minimal stent CSA did not differ significantly
etween the 2 groups, mean stent CSA and mean neointi-
al CSA were smaller in the DES group than in the BMS
roup; and the neointima volume index tended to be smaller in
he DES group as compared with the BMS group (0.42 
.12 vs. 0.51  0.09, respectively; p  0.069).
ing coronary artery in a 42-year-old male patient. Thirteen and a half years later,
cclusion at previous bare-metal stent site (arrow). (B) Intravascular ultrasound
ap rupture, evacuated intrastent plaque cavity, and thrombus formation. The
duplicated to allow annotation. a  typical Cordis stent struts (note: not all
separating the inner highly eccentric intrastent plaque from a thinner concentric
e fibrous cap; e  residual fibrous cap remnant; f  evacuated plaque cavity
b”); g  intraluminal thrombus. These features are virtually indistinguishablescend
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IVUS in Very Late Stent Thrombosis May 4, 2010:1936–42There were 17 stent malappositions in the DES group with
LST, but none in the BMS group (73.9% vs. 0%, respec-
ively; p  0.001). Of the 17 DES-treated patients with
LST, 11 had post-intervention IVUS; none had evidence of
cute stent malapposition, 6 had stent–vessel wall malapposi-
ion at the time of VLST, and 5 had VLST in the absence of
tent–vessel wall malapposition. In addition, 6 of 11 of these
atients with post-procedure IVUS had 6-month follow-up
VUS showing stent malapposition (Fig. 2). One patient with
ate stent malapposition at 6 months showed disappearance of
tent malapposition at the time of VLST, whereas another
atient without stent malapposition at 6 months had late stent
alapposition at the time of VLST. External elastic mem-
rane CSA was greatest at the site of stent malapposition and
easured 25.20 6.28 mm2. This was located at the proximal
tent segment in 35.3% of patients, at the stent body in 41.2%,
nd at the distal stent segment in 23.5% of patients.
Neointimal rupture within the stents was observed in 10
ES patients (43.5%) and 7 BMS patients (100%, p 0.010).
hus, in-stent neointimal rupture or reference segment plaque
upture was seen in 65.2% of DES VLST versus 100% of
MS VLST (p  0.143); and either late stent malapposition
r neointimal/plaque rupture accounted for all but 2 cases in
he overall cohort of BMS VLST and DES VLST. The DES
LST with plaque rupture was associated with larger mini-
um stent areas (6.7  1.4 mm2 vs. 5.1  1.4 mm2, p 
.019) and more neointima (volume index  0.46  0.11 vs.
.35  0.11, p  0.028) than DES VLST without plaque
upture. Finally, 2 BMS patients with VLST (28.6%) had
uperficial neointimal calcification within the BMS.
iscussion
his study showed that stent malapposition was unique to
ES-related VLST; it was not seen in BMS-related VLST.
Figure 2 Serial Changes in Stent Malapposition
Serial changes in stent malapposition after percutaneous coronary intervention (poonversely, there was more in-stent neointimal tissue with seointimal rupture in BMS-related VLST sites compared with
ES-related VLST sites. Although VLST occurs with both
MS and DES, our findings suggest that different biological
echanisms underlie BMS-related and DES-related VLST.
Stent thrombosis is acute thrombotic occlusion of the
tented segment that most often occurs within 30 days after
tent placement. Stent thrombosis can be classified according
o the timing of occurrence: acute (24 h after implantation),
ubacute (1 to 30 days after implantation), late (1 month to 1
ear after implantation), and very late (1 year after implan-
ation) (11). VLST was rare in the BMS era, but is being
ncreasingly reported in the DES era. The cumulative inci-
ence of DES-related stent thrombosis at 1 year ranges from
.5% to 1.5%, similar to that for BMS (12,13); but the risk of
LST is greater for DES than for BMS, with an ongoing
azard as high as 0.6% per year (14). Mechanisms underlying
LST may differ from those of early stent thrombosis (6,7,15).
elayed arterial healing with incomplete endothelialization
nd persistent fibrin or stent–vessel wall malapposition have
een suggested as possible mechanisms underlying VLST.
ate stent malapposition may develop because of vessel wall
emodeling and/or thrombus resorption.
The vessel wall appears to pull away from the stent struts
ecause of vessel remodeling or thrombus resorption, leading
o late stent malapposition. Whether this is related to the drug
r the polymer remains unknown and may vary among DES
ypes. In the present study, late stent malapposition was
bserved in 73.9% of patients with DES-related VLST,
omparable to that (77%) of previous reports (8). Furthermore,
f the 11 patients with serial IVUS imaging and VLST,
alapposition was late and acquired rather than acute and
ersistent.
Late stent malapposition occurs far more frequently with
ES than with BMS (9). Although the relationship between
), at 6-month follow-up, and at the time of very late stent thrombosis (VLST).st-PCItent malapposition and stent thrombosis remains unclear
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May 4, 2010:1936–42 IVUS in Very Late Stent Thrombosis8,9,16–18), stent malapposition may serve as a local nidus for
LST by allowing fibrin and platelet deposition (6,19,20). In
he current study, no BMS-treated patient who presented with
LST had stent–vessel wall malapposition.
Previously, we failed to identify late stent malapposition that
as routinely detected at 6 months as a predictor of subsequent
ES thrombosis (16). That failure may have been due to the
mall number of patients with late stent malapposition (n 
2), to the infrequent occurrence of VLST even among
atients with late stent malapposition, and to the dynamic
ature of stent malapposition even beyond 6 months, as was
een in some of the patients in the current cohort. In addition,
ur data suggest that the differences in reference diameter,
esion length, and stent length may contribute to the develop-
ent of VLST in patients treated with DES.
Although VLST is usually associated with DES, it is also an
ssue after BMS implantation, as seen in the current report.
owever, little attention has been paid to VLST after BMS
mplantation. A large retrospective study reported that the
umulative incidence of stent thrombosis after BMS implan-
ation was 0.5% at 30 days, 0.8% at 1 year, 1.3% at 5 years, and
.0% at 10 years (10). In the present study, plaque rupture
ithin the stents was identified in 100% of BMS-related
LST, and plaque rupture in reference artery segments was
dentified in 28.6% of BMS-related VLST. Atherosclerosis is
progressive disease, and neointima within the stents can be a
idus for new disease in both BMS and DES, but especially in
ES, where it seems to occur earlier probably because of
nflammatory response to the polymer (21,22). The longer
nterval from implantation to VLST in BMS than in DES was
onsistent with the longer time needed to develop intrastent
eoatherosclerotic plaque and plaque rupture.
We speculate that neoatherosclerotic lesions within the
MS may progress to tight stenosis and/or plaque rupture
21). Plaque rupture can expose the stent struts, in addition
o the lipid core, to trigger thrombus formation. Interest-
ngly, neointimal rupture within DES was also observed in
ur study, supporting the pathologic finding that neoath-
rosclerosis develops more rapidly within DES than within
MS (21,23). In addition, our study showed that disease
rogression with plaque rupture occurs in adjacent reference
egments during long-term follow-up, potentially contrib-
ting to thrombosis of the vessel.
The present study had several potential limitations. First,
VUS examination at the end of the index procedure was
ot available for one-half of the patients (52.2%); therefore,
hether stent malapposition was persistent or was acquired
uring follow-up procedure could not be determined in all
atients. Second, the number of patients with BMS-related
LST was small. Third, the time to VLST may be biased
y the sequential advent of the 2 stent types coupled with
he more recent interest in VLST and the time from
tenting to the data collection era. Further follow-up study
ay be needed to clarify this issue. Finally, IVUS has
nherent image quality limitations that may prevent distin-
uishing thrombi from plaques.onclusions
ur results suggest that different mechanisms underlie VLST
epending upon the stent type. Stent malapposition plays a key
ole in DES-related VLST whereas neoatherosclerosis with
laque rupture plays a key role in BMS-related VLST.
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